BRIEF—Grifols realigns management structure

Spanish plasma-derived drugmaker Grifols says that its board of directors has approved the realignment of the company’s management team to accelerate Grifols’ performance and simplify its corporate governance, ensuring a sharper focus on delivering results.

In addition to his role as executive chairman, Thomas Glanzmann has been appointed to the position of chief executive, effective immediately. He will be responsible for the company’s business decisions while creating and implementing its short- and long-term strategies with the management team.

Victor Grifols Deu will become chief operating officer, focused on managing the day-to-day business, with all operating functions reporting to him. He will continue as a member of the company’s board of directors.

Raimon Grifols, currently Grifols vice chairman, will in addition to his board duties assume the role of chief corporate officer, centered on optimizing the value of Grifols corporate affiliates and partnerships, as well as leading key corporate initiatives.

Thomas Glanzmann commented: “I am confident these changes will position Grifols for the next chapter of growth, helping accelerate our performance to deliver results and meet our commitments to all of the company’s stakeholders.”